Join us as we speak with John Wilcox, CEO, and Luis Blanco, CTO, of Diatech Diabetes
Sunday, 18 April 2021
5pm PDT/12am GMT
Don’t miss this exciting discussion about SmartFusion, a new system to monitor insulin delivery for accuracy and infusion set failure
Diatech, based in Memphis, TN, is developing SmartFusion: a system for insulin pumps that monitors insulin delivery for accuracy and infusion set failure. SmartFusion’s software could be integrated into an insulin pump or app and use data from the pump, continuous glucose monitor, and patient infusion habits to monitor the success of daily insulin dosages.
THE PROBLEM: Insulin infusions are administered through subcutaneous tissue injections to counteract a buildup of glucose in the blood throughout the day. Repeated insertions and chronic insulin exposure compromises the small volumes of subcutaneous tissue under the skin into which patients inject their syringes, pens and infusion set cannulas. The changes in subcutaneous tissue can lead to infusion site abnormalities, which could reduce the efficacy of the insulin being used and lead to hazardous consequences to those living with this diabetes.
THE SOLUTION: SmartFusion: a system for insulin pumps that monitors insulin delivery for accuracy and infusion set failure
John Wilcox, CEO and T1D, leads Diatech’s overall operations with a key focus on ensuring that the technology is designed around the needs of a person with diabetes.
Luis Blanco, CTO, works to craft Diatech’s ideas into physical form in hopes of changing the lives of patients and families through personalized technology and healthcare innovation.
Advisors include Dr. Rayhan Lal (Stanford endocrinology & T1D) and Dave Walton (T1D Exchange and T1D)